| Characteristic . | FTC/TDF + PI/r (N = 155) . | 3TC/ABC + PI/r (N = 156) . | Total (N = 311) . |
|---|---|---|---|
| Age, median (range), years | 46 (22, 66) | 46 (22, 75) | 46 (22, 75) |
| Male sex, No. (%) | 129 (83) | 134 (86) | 263 (85) |
| Race, No. (%) | |||
| White | 96 (62) | 106 (68) | 202 (65) |
| Black | 43 (28) | 44 (28) | 87 (28) |
| Asian | 4 (3) | 3 (2) | 7 (2) |
| Other | 12 (8) | 3 (2) | 15 (5) |
| Ethnicity | |||
| Hispanic/Latino | 38 (25) | 36 (23) | 74 (24) |
| Non-Hispanic/Latino | 117 (76) | 120 (77) | 237 (76) |
| HIV-1 RNA c/mL, No. (%) | |||
| <50 | 139 (90) | 145 (93) | 284 (91) |
| 50 to < 200 | 13 (8) | 10 (6) | 23 (8) |
| ≥200 | 3 (2) | 1 (1) | 4 (1) |
| Time since first ARV therapy, median (IQR), years | 4 (2.5, 6.9) | 3.7 (2.5, 6.7) | 3.8 (2.5, 6.7) |
| CD4 cell count, median (IQR), cells/mm3 | 532 (354, 725) | 532 (382, 728) | 532 (363, 725) |
| Comorbidities, No. (%) | |||
| Hyperlipidemia | 81 (52) | 96 (62) | 177 (57) |
| Hypertension | 51 (33) | 51 (33) | 102 (33) |
| Diabetes | 15 (10) | 17 (11) | 32 (10) |
| Lipid modifying agent, No. (%) | 67 (43) | 80 (51) | 147 (47) |
| PI stratification | |||
| Lopinavir/ritonavir | 48 (31) | 53 (34) | 101 (32) |
| Non-lopinavir/ritonavir | 107 (51) | 103 (49) | 210 (68) |
| Atazanavir/ritonavir | 62 (40) | 60 (38) | 122 (78) |
| Fosamprenavir/ritonavir | 34 (22) | 31 (20) | 65 (40) |
| Darunavir/ritonavir | 9 (6) | 11 (7) | 20 (13) |
| Other PI | 2 (1) | 1 (1) | 3 (2) |
| eGFR Cockcroft-Gault, mL/min (IQR) | 95 (79–110) | 96 (77–113) | … |
| Characteristic . | FTC/TDF + PI/r (N = 155) . | 3TC/ABC + PI/r (N = 156) . | Total (N = 311) . |
|---|---|---|---|
| Age, median (range), years | 46 (22, 66) | 46 (22, 75) | 46 (22, 75) |
| Male sex, No. (%) | 129 (83) | 134 (86) | 263 (85) |
| Race, No. (%) | |||
| White | 96 (62) | 106 (68) | 202 (65) |
| Black | 43 (28) | 44 (28) | 87 (28) |
| Asian | 4 (3) | 3 (2) | 7 (2) |
| Other | 12 (8) | 3 (2) | 15 (5) |
| Ethnicity | |||
| Hispanic/Latino | 38 (25) | 36 (23) | 74 (24) |
| Non-Hispanic/Latino | 117 (76) | 120 (77) | 237 (76) |
| HIV-1 RNA c/mL, No. (%) | |||
| <50 | 139 (90) | 145 (93) | 284 (91) |
| 50 to < 200 | 13 (8) | 10 (6) | 23 (8) |
| ≥200 | 3 (2) | 1 (1) | 4 (1) |
| Time since first ARV therapy, median (IQR), years | 4 (2.5, 6.9) | 3.7 (2.5, 6.7) | 3.8 (2.5, 6.7) |
| CD4 cell count, median (IQR), cells/mm3 | 532 (354, 725) | 532 (382, 728) | 532 (363, 725) |
| Comorbidities, No. (%) | |||
| Hyperlipidemia | 81 (52) | 96 (62) | 177 (57) |
| Hypertension | 51 (33) | 51 (33) | 102 (33) |
| Diabetes | 15 (10) | 17 (11) | 32 (10) |
| Lipid modifying agent, No. (%) | 67 (43) | 80 (51) | 147 (47) |
| PI stratification | |||
| Lopinavir/ritonavir | 48 (31) | 53 (34) | 101 (32) |
| Non-lopinavir/ritonavir | 107 (51) | 103 (49) | 210 (68) |
| Atazanavir/ritonavir | 62 (40) | 60 (38) | 122 (78) |
| Fosamprenavir/ritonavir | 34 (22) | 31 (20) | 65 (40) |
| Darunavir/ritonavir | 9 (6) | 11 (7) | 20 (13) |
| Other PI | 2 (1) | 1 (1) | 3 (2) |
| eGFR Cockcroft-Gault, mL/min (IQR) | 95 (79–110) | 96 (77–113) | … |
Abbreviations: ARV, antiretroviral; eGFR, epidermal growth factor receptor; FTC/TDF, emtricitabine/tenofovir disoproxil fumarate; HIV-1, human immunodeficiency virus; IQR, interquartile range; PI, protease inhibitor; 3TC/ABC, lamivudine/abacavir.
| Characteristic . | FTC/TDF + PI/r (N = 155) . | 3TC/ABC + PI/r (N = 156) . | Total (N = 311) . |
|---|---|---|---|
| Age, median (range), years | 46 (22, 66) | 46 (22, 75) | 46 (22, 75) |
| Male sex, No. (%) | 129 (83) | 134 (86) | 263 (85) |
| Race, No. (%) | |||
| White | 96 (62) | 106 (68) | 202 (65) |
| Black | 43 (28) | 44 (28) | 87 (28) |
| Asian | 4 (3) | 3 (2) | 7 (2) |
| Other | 12 (8) | 3 (2) | 15 (5) |
| Ethnicity | |||
| Hispanic/Latino | 38 (25) | 36 (23) | 74 (24) |
| Non-Hispanic/Latino | 117 (76) | 120 (77) | 237 (76) |
| HIV-1 RNA c/mL, No. (%) | |||
| <50 | 139 (90) | 145 (93) | 284 (91) |
| 50 to < 200 | 13 (8) | 10 (6) | 23 (8) |
| ≥200 | 3 (2) | 1 (1) | 4 (1) |
| Time since first ARV therapy, median (IQR), years | 4 (2.5, 6.9) | 3.7 (2.5, 6.7) | 3.8 (2.5, 6.7) |
| CD4 cell count, median (IQR), cells/mm3 | 532 (354, 725) | 532 (382, 728) | 532 (363, 725) |
| Comorbidities, No. (%) | |||
| Hyperlipidemia | 81 (52) | 96 (62) | 177 (57) |
| Hypertension | 51 (33) | 51 (33) | 102 (33) |
| Diabetes | 15 (10) | 17 (11) | 32 (10) |
| Lipid modifying agent, No. (%) | 67 (43) | 80 (51) | 147 (47) |
| PI stratification | |||
| Lopinavir/ritonavir | 48 (31) | 53 (34) | 101 (32) |
| Non-lopinavir/ritonavir | 107 (51) | 103 (49) | 210 (68) |
| Atazanavir/ritonavir | 62 (40) | 60 (38) | 122 (78) |
| Fosamprenavir/ritonavir | 34 (22) | 31 (20) | 65 (40) |
| Darunavir/ritonavir | 9 (6) | 11 (7) | 20 (13) |
| Other PI | 2 (1) | 1 (1) | 3 (2) |
| eGFR Cockcroft-Gault, mL/min (IQR) | 95 (79–110) | 96 (77–113) | … |
| Characteristic . | FTC/TDF + PI/r (N = 155) . | 3TC/ABC + PI/r (N = 156) . | Total (N = 311) . |
|---|---|---|---|
| Age, median (range), years | 46 (22, 66) | 46 (22, 75) | 46 (22, 75) |
| Male sex, No. (%) | 129 (83) | 134 (86) | 263 (85) |
| Race, No. (%) | |||
| White | 96 (62) | 106 (68) | 202 (65) |
| Black | 43 (28) | 44 (28) | 87 (28) |
| Asian | 4 (3) | 3 (2) | 7 (2) |
| Other | 12 (8) | 3 (2) | 15 (5) |
| Ethnicity | |||
| Hispanic/Latino | 38 (25) | 36 (23) | 74 (24) |
| Non-Hispanic/Latino | 117 (76) | 120 (77) | 237 (76) |
| HIV-1 RNA c/mL, No. (%) | |||
| <50 | 139 (90) | 145 (93) | 284 (91) |
| 50 to < 200 | 13 (8) | 10 (6) | 23 (8) |
| ≥200 | 3 (2) | 1 (1) | 4 (1) |
| Time since first ARV therapy, median (IQR), years | 4 (2.5, 6.9) | 3.7 (2.5, 6.7) | 3.8 (2.5, 6.7) |
| CD4 cell count, median (IQR), cells/mm3 | 532 (354, 725) | 532 (382, 728) | 532 (363, 725) |
| Comorbidities, No. (%) | |||
| Hyperlipidemia | 81 (52) | 96 (62) | 177 (57) |
| Hypertension | 51 (33) | 51 (33) | 102 (33) |
| Diabetes | 15 (10) | 17 (11) | 32 (10) |
| Lipid modifying agent, No. (%) | 67 (43) | 80 (51) | 147 (47) |
| PI stratification | |||
| Lopinavir/ritonavir | 48 (31) | 53 (34) | 101 (32) |
| Non-lopinavir/ritonavir | 107 (51) | 103 (49) | 210 (68) |
| Atazanavir/ritonavir | 62 (40) | 60 (38) | 122 (78) |
| Fosamprenavir/ritonavir | 34 (22) | 31 (20) | 65 (40) |
| Darunavir/ritonavir | 9 (6) | 11 (7) | 20 (13) |
| Other PI | 2 (1) | 1 (1) | 3 (2) |
| eGFR Cockcroft-Gault, mL/min (IQR) | 95 (79–110) | 96 (77–113) | … |
Abbreviations: ARV, antiretroviral; eGFR, epidermal growth factor receptor; FTC/TDF, emtricitabine/tenofovir disoproxil fumarate; HIV-1, human immunodeficiency virus; IQR, interquartile range; PI, protease inhibitor; 3TC/ABC, lamivudine/abacavir.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
